Day: May 29, 2024

Business Highlights: Full year revenues increased over 37% year over year to $145.6 million Full year gross margin expansion of 1,620 basis points over the prior year Generated $2.1 million of operating cash flow, helping to further strengthen the balance sheet Company to host conference call tomorrow, May 30 at 10:00 am ET AYER, Mass., May 29, 2024 (GLOBE NEWSWIRE) — AMSC (Nasdaq: AMSC), a leading system provider of megawatt-scale power resiliency solutions that orchestrate the rhythm and harmony of power on the grid™, and that protect and expand the capability and resiliency of our Navy’s fleet, today reported financial results for its fourth quarter and fiscal year ended March 31, 2024 (“fiscal 2023”). Revenues for the fourth quarter of fiscal 2023 were $42.0 million compared with $31.7 million for the same...

PALO ALTO, Calif., May 29, 2024 (GLOBE NEWSWIRE) — HP (NYSE: HPQ) Second quarter GAAP diluted net earnings per share (“EPS”) of $0.61, within the previously provided outlook of $0.58 to $0.68 per share Second quarter non-GAAP diluted net EPS of $0.82, within the previously provided outlook of $0.76 to $0.86 per share Second quarter net revenue of $12.8 billion, down 0.8% from the prior-year period Second quarter net cash provided by operating activities of $0.6 billion, free cash flow of $0.5 billion Second quarter returned $0.4 billion to shareholders in the form of dividends and share repurchases   HP Inc.’s fiscal 2024 second quarter financial performance   Q2 FY24 Q2 FY23 Y/Y GAAP net revenue ($B) $ 12.8   $ 12.9   (0.8)% GAAP operating margin   7.4%     5.8%   1.6 pts GAAP net earnings ($B) $ 0.6   $ 1.1   (42)% GAAP...

SAN JOSE, Calif., May 29, 2024 (GLOBE NEWSWIRE) — Credo Technology Group Holding Ltd (Nasdaq: CRDO) (“Credo”), an innovator in providing secure, high-speed connectivity solutions that deliver improved energy efficiency, today reported financial results for the fourth quarter and full fiscal year 2024, ended April 27, 2024. Fourth Quarter of Fiscal Year 2024 Financial Highlights Revenue of $60.8 million grew by 89.4% year over year GAAP gross margin of 65.8% and non-GAAP gross margin of 66.1%   GAAP operating expenses of $47.8 million and non-GAAP operating expenses of $32.7 million GAAP net loss of $10.5 million and non-GAAP net income of $11.8 million GAAP diluted net loss per share of $0.06 and non-GAAP diluted net income per share of $0.07 Ending cash and short-term investment balance of $410.0 million Management Commentary Bill...

• Total Revenues of $128.1M, up 13% year-over-year • Subscription Revenues of $110.4M, up 13% year-over-year • GAAP Operating Margin of (3)%, up ~500 basis points year-over-year • Non-GAAP Operating Margin of 19%, up ~900 basis points year-over-year WILMINGTON, N.C., May 29, 2024 (GLOBE NEWSWIRE) — nCino, Inc. (NASDAQ: NCNO), a pioneer in cloud banking for the global financial services industry, today announced financial results for the first quarter of fiscal year 2025, ended April 30, 2024. “Building on our fourth quarter momentum, we had a great start to the year, achieving our highest first-quarter gross sales in Company history,” said Pierre Naudé, Chairman and CEO at nCino. “Our strong sales execution produced wins across multiple markets, highlighting the breadth and depth of our product portfolio and the effectiveness...

Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and other therapeutic areas over this fiscal year ending March 31, 2025 Topline data from the batoclimab Myasthenia Gravis (MG) study is also expected over this fiscal year and further potentially registrational development in MG with IMVT-1402 is expected to begin in the same timeframe Immunovant has decided to run the batoclimab trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) longer prior to unblinding period 1 in order to better ensure that the data from the batoclimab trial, combined with learning from other CIDP trials, can be used to optimize the IMVT-1402 CIDP trial design  Detailed results from the batoclimab study in...